PharmiWeb.com - Global Pharma News & Resources
01-Nov-2024

Latest Innovation Scorecard for the NHS in England published by the NHSBSA

The NHS Business Services Authority (NHSBSA) has published the latest Innovation Scorecard as an Official Statistic, having taken over this responsibility from NHS England in April 2024, who previously produced and published the scorecard. 

The latest Innovation Scorecard shows that there was a 72.2% increase in prescribed medicines from July 2023 to June 2024 compared to the previous 12 months. During the same period, 14 medicine groupings were used more frequently than in the previous 12 months.  

The Innovation Scorecard, designed solely to monitor the uptake of approved treatments, reports on the use of individual medicines and medicine technologies in the NHS in England that have been recommended by the National Institute for Health and Care Excellence (NICE) for use in the NHS. It is presented in an interactive dashboard format. 

The scorecard aims to improve transparency within the NHS regarding which treatments recommended by NICE are available at a local level, including Trusts, Integrated Care Boards (ICBs), as well as national and NHS England regional levels. It can be used by local NHS organisations to monitor progress in implementing NICE Technology Appraisal (TA) recommendations. These appraisals determine whether a drug, medical device, or surgical procedure should be funded by the NHS. 

The scorecard analyses 206 medicines, with 16 medicines added since the previous Innovation Scorecard which covered January 2023 to December 2023. These medicines are now organised into 18 medicine groupings, combining different treatment options used to manage the same condition. The medicine groupings are for:  

  • Acute coronary syndrome 
  • COVID-19
  • Cystic fibrosis
  • EGFR Non-small-cell lung cancer
  • hATTR polyneuropathy 
  • Hepatitis C
  • Icosapent ethyl
  • Long-term insomnia
  • Metastatic prostate cancer
  • Migraine
  • Multiple sclerosis
  • Obesity
  • Primary hypercholesterolaemia
  • Severe asthma
  • SGLT-2 inhibitors
  • Smoking cessation
  • Stroke (separate groupings for GP and hospital)

To access the full publication, go to: NICE Technology Appraisals in the NHS in England (Innovation Scorecard) - to June 2024 | NHSBSA 

Editor Details

Last Updated: 01-Nov-2024